

Annals of the Rheumatic Diseases The EULAR Journal

Editor

Leo van de Putte (The Netherlands)

Associate Editors

Thomas Bardin (France) Johannes Bijlsma (The Netherlands) Gerd Burmester (Germany)

Methodological Adviser

Jaap Fransen (The Netherlands)

Editorial Board

M Aringer (Austria) P Bacon (UK) F Berenbaum (France) M Boers (The Netherlands) D Boumpas (Greece) B Bresnihan (Ireland) H Capell (UK) M Cutolo (Italy) G Firestein (USA) P Goupille (France) E Gravallese (USA)

F Guillemin (France) G Herrero-Beaumont (Spain) F Houssiau (Belgium) T Huizinga (The Netherlands) C Jorgensen (France)

G Kollias (Greece) T Kvien (Norway) M Leirisalo-Repo (Finland) F Luijten (Belgium)

W Gross (Germany)

H-M Lorenz (Germany) W Maslinski (Poland) M Matucci Cerinic (Italy)

Advisory Committee

W vd Berg (The Netherlands) S Bombardieri (Italy) F Breedveld (The Netherlands) L Crofford (USA) J-M Dayer (Switzerland) M Doherty (UK) M Dougados (France) J Edmonds (Australia) P Emery (UK) D Furst (USA) S Gay (Switzerland) J Kalden (Germany) E Keystone (Canada) L Klareskog (Sweden)

Bevrah Hahn (USA) Frank Wollheim (Sweden) Anthony Woolf (UK)

K Nishioka (Japan) M Nurmohamed (The Netherlands) S Özen (Turkey) T Pap (Germany) E Pascual Gómez (Spain) L Punzi (Italy) L Rönnblom (Sweden)

G Schett (Austria) J Da Silva (Portugal) H Schulze-Koops (Germany) A So (Switzerland)

T Sokka (USA) D Symmons (UK) P-P Tak (The Netherlands) A Tyndall (Switzerland)

B Rozman (Slovenia)

A Tzioufas (Greece) J Vencovsky (Czech Republic)

M Weisman (USA) H Yazici (Turkey) Editor, BMJ

P Lipsky (USA) S Lohmander (Finland) R Maini (UK) E M Mola (Spain) H Moutsoupolos (Greece) J O'Dell (USA) K Pavelka (Czech Republic)

J Rovensky (Slovakia) Y Shoenfeld (Israel) J Smolen (Austria) W van Venroov (The Netherlands) E Veys (Belgium) A Wiik (Denmark)

Guidelines for Authors and Reviewers

Guidance for authors and reviewers can be found at http://ard.bmj.com/ifora All papers must be submitted via Bench>Press at http://submit-ard.bmj.com

Disclaimer

Annals of the Rheumatic Diseases is published by BMJ Publishing Group Ltd, a wholly owned subsidiary of the British Medical Association, and the European League Against Rheumatism.

The BMA grants editorial freedom to the Editor of the *Annals of the Rheumatic Diseases*. The *Annals of the Rheumatic Diseases* follows guidelines on editorial independence produced by the World Association of Medical Editors and the code on good publication practice of the Committee on Publication Ethics.

The Annals of the Rheumatic Diseases is intended for medical professionals and is provided without warranty, express or implied. Statements in the journal are the responsibility of their authors and advertisers and not authors' institutions, the BMJ Publishing Group Ltd, The European League Against Rheumatism or the BMA unless otherwise specified or determined by law. Acceptance of advertising does not imply endorsement. To the fullest extent permitted by law, the BMJ Publishing Group Ltd shall not be liable for any loss, injury or damage resulting from the use of the Annals of the Rheumatic Diseases or any information in it whether based on contract, tort, or otherwise. Readers are advised to verify any information they choose to rely on.

Subscription Information


ISSN 0003-4967 (print); 1468-2060 (online)

Copyright

© 2007 BMJ Publishing Group Ltd and European League Against Rheumatism. All rights reserved; no part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise without the prior permission of Annals of the Rheumatic Diseases

- Authors are required to grant *Annals of the Rheumatic Diseases* an exclusive licence to publish; further details available online at
- http://annrheumdis.com/ifora/licence.dtl

 Annals of the Rheumatic Diseases is published by BMJ Publishing Group, typeset by The Charlesworth Group, and printed in the UK on acid-free
- paper by Cambrian Printers Limited, Aberystwyth
 Periodicals postage paid, Rahway, NJ. Postmaster: send address changes to: Annals of the Rheumatic Diseases, c/o Mercury Airfreight International Ltd, 365 Blair Road, Avenel, NJ 07001, USA



Cover image: part of "Die drei Lebensalter der Frau", Gustav Klimt, 1905, National Gallery of Modern Art, Rome.

contents ARD

Volume 66 Supplement III November 2007

Preface

Advances in targeted therapies IX F C Breedveld 3

Consensus statement

Advances in targeted therapies IX F C Breedveld A J R Kalden, J S Smolen

Sensus statement

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007 D E Furst, F C Breedveld, J R Kalden, J S Smolen, G R Burmester, J Sieper, P Emery, E C Keystone, M H Schiff, P Mease, P L C M van Riel, R Fleischmann, M H Weismann, M E Weinblatt ͺas on⋅1 November

Opening lectures

Actin cytoskeleton dynamics linked to synovial fibroblast activation as a novel pathogenic principle in TNF-driven arthritis Y Vasilopoulos, V Gkretsi, M Armaka, V Aidinis G Kollias

New therapies for sepsis: focus on the interleuking (IL)12 family member IL27 M F Neurath
Interpreting measurements of physical function in clinical trials M M Ward iii29

iii32

iii35 Thoughts on health economics in rheumatoid arthritis G Kobelt

Looking at clinical trials and more

.....

iii40 Minimal clinically important improvement/ difference (MCII/MCID) and patient acceptable symptom state (PASS): what do these concepts mean? T K Kvien, T Heiberg, K B Hagen on March

Joint remodelling in inflammatory disease iii42 G Schett

Animal models

al models

Amplifying elements of arthritis and joint destruction W B van den Berg, P L van Lent, L A B Joosten, S Abdollahi-Roodsaz, M I Koenders

targets I

Schnurri-3 is an essential regulator of osteoblase function and adult bone mass D C Jones, iii45

Novel targets I

iii49 function and adult bone mass D C Jones, by copyrigh M N Wein, L H Glimcher

α-MSH related peptides: a new class of antiiii52 inflammatory and immunomodulating drugs T A Luger, T Brzoska

Insights from investigator-driven trials and genetics

iii56 Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility M F Bakker,



This journal is a member of and subscribes to the principles of the Committee on Publication Ethics

contents ARD

Volume 66 Supplement III November 2007

		J W G Jacobs, S M M Verstappen, J W J Bijlsma	iii77	Update on toll-like receptor-directed therapies for human disease <i>K Tse, A A Horner</i>		
	The l	upus connection	iii81	Could toll-like receptors provide a missing link in chronic inflammation in rheumatoid arthritis? Lessons from a study on human rheumatoid tissue S M Sacre, S K Drexler, E Andreakos, M Feldmann, F M Brennan, B M J Foxwell		
	iii61	Disease activity assessment in SLE: do we have the right instruments? M Petri				
	iii65	Systemic lupus erythematosus: new molecular targets J C Crispín, V C Kyttaris, Y-T Juang, G C Tsokos				
	1 1 July, O C 130kos		Novel targets III			
	• • • • • • • • • • • • • • • • • • • •	_		Novel targets III		
Novel targets II		iii87	Interplay between pathogenic Th17 and			
	iii70	Emerging roles of vasoactive intestinal peptide: a new approach for autoimmune therapy E Gonzalez-Rey, P Anderson, M Delgado		regulatory T cells M Oukka		
			iii91	Regulatory T cells and toll-like receptors: regulating the regulators R Sutmuller, A Garritsen, G J Adema		